RESEARCH REPORT Dave Levitan The combination of whole-brain radiation therapy and the EGFR inhibitor erlotinib showed a promising response rate and was well tolerated in a new phase II trial of patients with brain metastases from non-small-cell lung cancer.
REVIEW ARTICLE Elgene Lim, Nancy U. Lin;ONCOLOGY Vol. 26 No. 7 This review will focus on the breast cancer subtypes with the highest incidence of breast cancer brain metastases and will characterize differences in the clinical behavior of brain metastases that arise from these different subtypes.
The development of metastatic disease in patients with paraganglioma is an unusual and challenging event. This case report and review describes the specific features of this disease and the multiple therapeutic options.
• An Uncommon Manifestation of an Uncommon Disease
The authors address several commonly cited beliefs that have hindered the development of therapeutic agents for central nervous system malignancies, and advance reasons that they feel justify including patients with brain metastases in clinical trials of new therapeutic approaches for lung cancer.
• Lung Cancer-Related Brain Metastases: Further Considerations
A healthy 24-year-old male presented with a history of several months of poorly localized headaches and blurred vision. MRI of the brain demonstrated a multi-lobulated mass. Based on the radiographic appearance of the mass, what is the most likely diagnosis?